The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Poster Session (P808-P815)
-
October 8, 2024
-
0 min
Clinical Scorecard: 50th Annual Conference of the European Society for Blood and Marrow Transplantation: Poster Session on Patient Advocacy (P808-P815)
At a Glance
| Category | Detail |
|---|---|
| Condition | Lymphoma and Chronic Lymphocytic Leukaemia (CLL) |
| Key Mechanisms | Utilization of autologous haematopoietic stem cell transplant (aHSCT) and other therapies including chemotherapy, immunotherapy, radiation, steroids, and CAR-T |
| Target Population | Patients with lymphoma or CLL globally, across multiple subtypes |
| Care Setting | Hematology/Oncology treatment centers offering stem cell transplantation and multi-professional prehabilitation services |
Key Highlights
- Younger patients are significantly more likely to receive aHSCT; biological sex is not a predictor of utilization.
- Regional heterogeneity exists in aHSCT use, highest in Middle East and Africa (31%) and lowest in North America (4%).
- Patients receiving aHSCT often require multiple therapeutic regimens; over 60% experience relapse and CAR-T use is elevated in this group.
Guideline-Based Recommendations
Diagnosis
- Identify lymphoma or CLL subtype to guide treatment planning including consideration of aHSCT.
Management
- Consider aHSCT as part of multi-modality treatment especially in younger patients and certain lymphoma subtypes.
- Incorporate novel therapies such as CAR-T and bispecific antibodies to improve outcomes in aggressive disease.
- Implement multi-professional prehabilitation including dietetic, physiotherapy, pharmacy, occupational therapy, and psychological support prior to HSCT.
Monitoring & Follow-up
- Monitor for relapse post-aHSCT given high relapse rates (~60%).
- Assess patient-reported outcomes and experience measures to optimize supportive care.
Risks
- Relapse remains a significant risk post-aHSCT.
- Nutritional challenges during HSCT require proactive dietetic intervention to reduce weight loss and improve feeding tolerance.
Patient & Prescribing Data
5280 patients with lymphoma or CLL from 66 countries
aHSCT utilization varies by subtype and region; majority receiving aHSCT also receive additional therapies; CAR-T therapy is more common in aHSCT recipients.
Clinical Best Practices
- Use multi-disciplinary prehabilitation services to improve patient outcomes and experience before HSCT.
- Provide clear, concise dietetic counseling to empower patients in dietary management during HSCT.
- Support equitable access to all therapeutic modalities globally to improve lymphoma outcomes.
References
- European Society for Blood and Marrow Transplantation Annual Meeting
- Lymphoma Coalition Global Patient Survey 2022
- Macmillan Cancer Support - Principles and guidance for prehabilitation
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
